Trial Profile

Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous-muscle-precursor-cells-MUVON-Therapeutics (Primary)
Indications Urinary-Stress-Incontinence
Focus Therapeutic Use
Acronyms SUISSE MPC 2

Most Recent Events

09 Jan 2025 According to a MUVON Therapeutics media release, company announced interim data from this trial and On the basis of the interim data, the international Data Safety Monitoring Board recommended study continuation, putting the company on track for the release of the final data from the completed phase 2 study in Q3 2025.
06 Nov 2022 Status changed from not yet recruiting to recruiting.
02 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com